Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-12-12
2006-12-12
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S296000
Reexamination Certificate
active
07148352
ABSTRACT:
The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75NTRcommon neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75NTRcomprises, particularly when bound to nerve growth factor, at least two of the following: (1) a first electronegative atom or functional group positioned to interact with Lys34of nerve growth factor; (2) a second electronegative atom or functional group positioned to interact with Lys95of nerve growth factor; (3) a third electronegative atom or functional group positioned to interact with Lys88of nerve growth factor; (4) a fourth electronegative atom or functional group positioned to interact with Lys32of nerve growth factor; and (5) a hydrophobic moiety which interacts with the hydrophobic region formed by Ile31, Phe101and Phe86of nerve growth factor.
REFERENCES:
patent: 3821383 (1974-06-01), Sestanj
patent: 4204063 (1980-05-01), Brana et al.
patent: 4254109 (1981-03-01), Sestanj
patent: 4874863 (1989-10-01), Brana et al.
patent: 5183821 (1993-02-01), Brana et al.
patent: 5342942 (1994-08-01), Jaen et al.
patent: 5420137 (1995-05-01), Brana et al.
patent: 5552544 (1996-09-01), Bra na et al.
patent: 5554622 (1996-09-01), Brana
patent: 5616589 (1997-04-01), Keilhauer et al.
patent: 6029114 (2000-02-01), Shamovsky et al.
patent: 6291247 (2001-09-01), Riopelle et al.
patent: 6300331 (2001-10-01), Noguchi et al.
patent: 43963/09 (2000-01-01), None
patent: 2323555 (1974-08-01), None
patent: 3707652 (1988-09-01), None
patent: 0 206 322 (1986-12-01), None
patent: 0 268 093 (1988-05-01), None
patent: 2 521 139 (1983-08-01), None
patent: WO 98/17278 (1998-04-01), None
patent: WO 98/171278 (1998-04-01), None
patent: WO 98/34632 (1998-08-01), None
patent: WO 98/52919 (1998-11-01), None
patent: WO 00/00472 (2000-01-01), None
Brana, M.F., et al. “Enediynes as Antitumor Compounds: Synthesis of Tetrahydropyridine Derivatives”, J. Org. Chem., 61:1369-1374 (1996).
Brana, M.F., et al. “Synthesis and cytostatic activity of benz(de)isoquinolin-1,3-diones. Structure-activity relationships”, Eur. J. Med. Chem-Chimca Therapeutica, 16(3): 207-212 (May-Jun. 1981).
Arient, J. and Marhan J., Imidazolfarbstoffe VI. Synthese und Eigenschaften des 1,2-Naptholylenbenzimidazols:, Collection Czechoslov, Chem. Commun. 26: 2774-2780 (1961).
Nishizaki, S., Infrared spectra of N-substituted naphthalimides, Nippon Kagaki Zasshi 86(7): 696-9 (1965) (Japan). (From Chem. Abstracts, 1966, 64 (3), Abstract No. 3321e).
Jaen, J.C. et al., “Kynurenic Acid Derivatives Inhibit the Binding of Nerve Growth Factor (NGF) to the Low-Affinity p75 NGF Receptor”, J. Med. Chem. 38: 4439-4445 (1995).
Spiegel, K. et al., “PD 90780, A Non Peptide Inhibitor of Nerve Growth Factor's Binding to the p75 NGF Receptor”, Biochemical and Biophysical Research Communications 217(2): 488-494 (Dec. 14, 1995).
Owolabi, J.B. et al., “Characterization of Antiallodynic Actions of ALE-0540, a Novel Nerve Growth Factor Receptor Antagonist, in the Rat”, J. of Pharmacology and Experimental Therapeutics 289(3): 1271-1276 (1999).
Bailleux, V. et al., “Synthesis and Anticonvulsant Activity of Some N-Phenylphthalimides”, Chem. Pharm. Bull. 42(9): 1817-1821 (1994).
Bailleux, V. et al., “Anticonvulsant activity of some 4-amino-N-phenylphthalimides and N-(3-amino-2-methylphenyl)phthalimides)”, Biomed & Pharmacother 48: 95-101 (1994).
Shibata, Y. et al., “Phenylphthalimides with Tumor Necrosis Factor Alpha Production-Enhancing Activity”, Chem. Pharm. Bull. 44(1): 156-162 (1996).
Chapman, J.M. Jr. et al., “Hypolipidemic Activity of Phthalimide Derivatives. 2. N-Phenylphthalimide and Derivatives”, J. Med. Chem. 26: 237-243 (1983).
Chapman, J.M. Jr. et al., “Hypolipidermic Activity of Phthalimide Derivatives. 3. A Comparison of Phthalimide and 1,2-Benisothiazolin-3-one 1,1-Dioxide Derivatives to Phthalimidine and 1,2-Benzisothiazoline 1,1-Dioxide Congeners”, J. Med. Chem. 26: 243-246 (1983).
Chapman, J.M. Jr. et al., “Hypolipidemic Activity of Phthalimide Derivatives IV: Further Chemical Modification and Investigation of the Hypolipidemic Activity of N-Substituted Imides”, J. Pharmaceutical Sciences 72(11): 1344-1347 (1983).
Chapman, J.M. Jr. et al., “Hypolipidemic Activity of Phthalimide Derivatices V: Reduced and Hydrolytic Products of Simple Cyclic Imides”, J. Pharmaceutical Sciences 73(10): 1482-1484 (1984).
Tyman J.H.P., “Fluorescent naphthalimide dyes”, Chemical Abstract 108: 7506 (1997).
Chemical Abstracts 88:154305.
Szadowski et al., “Przemysl Chemizny” 57(2): 70-74 (1978).
Bailleux, V. et al., “Comparative Anticonvulsant Activity and Neurotoxicity of 4-Amino-N-(2,6-Dimethylphenyl)Phthalimide and Prototype Antiepileptic Drugs in Mice and Rats,”Epilepsia 36(6):559-565 (1995).
Marone Sandra
Riopelle Richard J.
Ross Gregory M.
Shamovsky Igor L.
Weaver Donald F.
Nassif Omar A.
Queen's University at Kingston
Seaman D. Margaret
LandOfFree
Method of inhibiting neurotrophin-receptor binding does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting neurotrophin-receptor binding, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting neurotrophin-receptor binding will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3705598